These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 22188558

  • 1. Serum testosterone levels in non-dosed females after secondary exposure to 1.62% testosterone gel: effects of clothing barrier on testosterone absorption.
    Stahlman J, Britto M, Fitzpatrick S, McWhirter C, Testino SA, Brennan JJ, Zumbrunnen TL.
    Curr Med Res Opin; 2012 Feb; 28(2):291-301. PubMed ID: 22188558
    [Abstract] [Full Text] [Related]

  • 2. Effect of application site, clothing barrier, and application site washing on testosterone transfer with a 1.62% testosterone gel.
    Stahlman J, Britto M, Fitzpatrick S, McWhirter C, Testino SA, Brennan JJ, Zumbrunnen TL.
    Curr Med Res Opin; 2012 Feb; 28(2):281-90. PubMed ID: 22188557
    [Abstract] [Full Text] [Related]

  • 3. Effects of skin washing on systemic absorption of testosterone in hypogonadal males after administration of 1.62% testosterone gel.
    Stahlman J, Britto M, Fitzpatrick S, McWhirter C, Testino SA, Brennan JJ, Zumbrunnen TL.
    Curr Med Res Opin; 2012 Feb; 28(2):271-9. PubMed ID: 22185431
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study.
    Wang C, Berman N, Longstreth JA, Chuapoco B, Hull L, Steiner B, Faulkner S, Dudley RE, Swerdloff RS.
    J Clin Endocrinol Metab; 2000 Mar; 85(3):964-9. PubMed ID: 10720024
    [Abstract] [Full Text] [Related]

  • 5. Preventing secondary exposure to women from men applying a novel nestorone/testosterone contraceptive gel.
    Yuen F, Wu S, Thirumalai A, Swerdloff RS, Page ST, Liu PY, Dart C, Wu H, Blithe DL, Sitruk-Ware R, Long J, Bai F, Hull L, Bremner WJ, Anawalt BD, Wang C.
    Andrology; 2019 Mar; 7(2):235-243. PubMed ID: 30556332
    [Abstract] [Full Text] [Related]

  • 6. A novel testosterone 2% gel for the treatment of hypogonadal males.
    Dobs AS, McGettigan J, Norwood P, Howell J, Waldie E, Chen Y.
    J Androl; 2012 Mar; 33(4):601-7. PubMed ID: 21979302
    [Abstract] [Full Text] [Related]

  • 7. Reduction in 24-hour plasma testosterone levels in subjects who showered 15 or 30 minutes after application of testosterone gel.
    de Ronde W, Vogel S, Bui HN, Heijboer AC.
    Pharmacotherapy; 2011 Mar; 31(3):248-52. PubMed ID: 21361734
    [Abstract] [Full Text] [Related]

  • 8. Transdermal testosterone gel: pharmacokinetics, efficacy of dosing and application site in hypogonadal men.
    Meikle AW, Matthias D, Hoffman AR.
    BJU Int; 2004 Apr; 93(6):789-95. PubMed ID: 15049991
    [Abstract] [Full Text] [Related]

  • 9. Transfer of transdermally applied testosterone to clothing: a comparison of a testosterone patch versus a testosterone gel.
    Mazer N, Fisher D, Fischer J, Cosgrove M, Bell D, Eilers B.
    J Sex Med; 2005 Mar; 2(2):227-34. PubMed ID: 16422890
    [Abstract] [Full Text] [Related]

  • 10. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men.
    Swerdloff RS, Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Longstreth J, Berman N.
    J Clin Endocrinol Metab; 2000 Dec; 85(12):4500-10. PubMed ID: 11134099
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetic comparison of two nicotine transdermal systems, a 21-mg/24-hour patch and a 25-mg/16-hour patch: a randomized, open-label, single-dose, two-way crossover study in adult smokers.
    DeVeaugh-Geiss AM, Chen LH, Kotler ML, Ramsay LR, Durcan MJ.
    Clin Ther; 2010 Jun; 32(6):1140-8. PubMed ID: 20637967
    [Abstract] [Full Text] [Related]

  • 12. One-year efficacy and safety study of a 1.62% testosterone gel in hypogonadal men: results of a 182-day open-label extension of a 6-month double-blind study.
    Kaufman JM, Miller MG, Fitzpatrick S, McWhirter C, Brennan JJ.
    J Sex Med; 2012 Apr; 9(4):1149-61. PubMed ID: 22321357
    [Abstract] [Full Text] [Related]

  • 13. Skin reactions in a phase 3 study of a testosterone topical solution applied to the axilla in hypogonadal men.
    Muram D, Melby T, Alles Kingshill E.
    Curr Med Res Opin; 2012 May; 28(5):761-6. PubMed ID: 22458919
    [Abstract] [Full Text] [Related]

  • 14. The long-term efficacy and safety of a testosterone mucoadhesive buccal tablet in testosterone-deficient men.
    Dinsmore WW, Wyllie MG.
    BJU Int; 2012 Jul; 110(2):162-9. PubMed ID: 22288877
    [Abstract] [Full Text] [Related]

  • 15. Comparative pharmacokinetics of three doses of percutaneous dihydrotestosterone gel in healthy elderly men--a clinical research center study.
    Wang C, Iranmanesh A, Berman N, McDonald V, Steiner B, Ziel F, Faulkner SM, Dudley RE, Veldhuis JD, Swerdloff RS.
    J Clin Endocrinol Metab; 1998 Aug; 83(8):2749-57. PubMed ID: 9709942
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety study of 1.62% testosterone gel for the treatment of hypogonadal men.
    Kaufman JM, Miller MG, Garwin JL, Fitzpatrick S, McWhirter C, Brennan JJ.
    J Sex Med; 2011 Jul; 8(7):2079-89. PubMed ID: 21492400
    [Abstract] [Full Text] [Related]

  • 17. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
    Darwish M, Tempero K, Kirby M, Thompson J.
    Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
    [Abstract] [Full Text] [Related]

  • 18. The effects of skin-to-skin contact, application site washing, and sunscreen use on the pharmacokinetics of estradiol from a metered-dose transdermal spray.
    Schumacher RJ, Gattermeir DJ, Peterson CA, Wisdom C, Day WW.
    Menopause; 2009 May; 16(1):177-83. PubMed ID: 18779758
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics and relative bioavailability of absorbed testosterone after administration of a 1.62% testosterone gel to different application sites in men with hypogonadism.
    Miller J, Britto M, Fitzpatrick S, McWhirter C, Testino SA, Brennan JJ, Zumbrunnen TL.
    Endocr Pract; 2011 May; 17(4):574-83. PubMed ID: 21454244
    [Abstract] [Full Text] [Related]

  • 20. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
    Vaughan D, Speed J, Medve R, Andrews JS.
    Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.